Experimental malaria vaccine aims to block parasite growth
NCT ID NCT05978037
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This trial tests an experimental malaria vaccine called RH5.2-VLP, given with an adjuvant (Matrix-M) to boost the immune response. Healthy adults aged 18–45 receive three doses, and some volunteers are later exposed to malaria parasites in a controlled setting to see if the vaccine prevents illness. The study evaluates safety, immune response, and the vaccine's ability to reduce parasite multiplication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental malaria vaccine called RH5.2-VLP, given with Matrix-M adjuvant
- What this could lead to
- If successful, this vaccine could help prevent malaria illness and reduce deaths from this major global disease.
- What could go wrong
- This is an early-phase trial with only 41 participants, so results may not apply broadly. The vaccine is being tested for the first time in humans, and its safety and effectiveness are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre for Clinical Vaccinology & Tropical Medicine (CCVTM)
Oxford, Oxfordshire, OX3 7LE, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for the tiniest malaria patients: a safer treatment for infants under 5 kg
- Could a simple device help curb malaria in children?
- New malaria drug interaction study launches in healthy volunteers
- Rare disease drug shows promise in reducing infections
- New malaria shots could replace daily pills
- New antibody shot shows promise against malaria in early trial